Clinical Trials Logo
  1. Home
  2. Growth Failure
  3. NCT03730883

The Effect of Early Versus Standard Central Line Removal on Growth of Very Low Birth Weight Premature Infants

Growth Failure Clinical Trial

Official title:
The Effect of Early Versus Standard Central Line Removal on Growth of Very Low Birth Weight Premature Infants: A Non-inferiority, Randomized Controlled Trial

Clinical Trial Summary

This study compares two different regimens of a central line removal in respect to weight at 36 weeks postmenstrual age in very low birth weight (VLBW) preterm infants. Half of participants will have a central line removed at ≥100 ml/kg/d, while the other half will have a central line removed at ≥ 140 ml/kg/day.

Clinical Trial Description

Eligible infants will be randomized in equal proportions between two groups. In the first group (group A - early central line removal) central line will be removed at the time the infant reaches 100 ml/kg/d of enteral intake. In the second group (group B - standard central line removal) central line will be removed at the time the infant reaches 140 ml/kg/d of enteral intake (full enteral intake). Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present: - necessity of administration of drugs that must be given via central venous access, - necessity of administration of drugs that must be given intravenously along with difficulties to secure peripheral venous access, - necessity of prolonged (> 7 days) administration of drugs that must be given intravenously, - necessity to continue parenteral nutrition along with difficulties to secure peripheral venous access. Assessment of feedings tolerance will be at discretion of the physician taking care for the infant. After central line removal, infants in group A will continue to receive parenteral nutrition via peripheral venous access at the discretion of the physician taking care for the infant. The solution used to continue parenteral nutrition via peripheral venous access will contain at maximum 2,5% amino acids, 10% glucose and no calcium or phosphate preparations to ensure fluid's osmolality will not exceed 900 mOsm/l and the solution will be well tolerated when administered via peripheral vein. Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03730883
Study type Interventional
Source Princess Anna Mazowiecka Hospital, Warsaw, Poland
Contact
Status Active, not recruiting
Phase N/A
Start date January 26, 2019
Completion date February 1, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04226586 - Nutritional Stimulation of Growth in Children With Short Stature N/A
Terminated NCT03016195 - Evaluation of the Normal Range of Urinary Sodium Levels in Healthy Newborn Babies N/A
Active, not recruiting NCT01809548 - Preterm Infants on Early Solid Foods N/A
Completed NCT01475357 - Intestinal Function in Neonates With Complex Congenital Heart Disease N/A
Completed NCT02136966 - Joint Infant and Young Child Nutrition Program and Malnutrition Prevention N/A
Active, not recruiting NCT04565314 - ELICIT 2.0: Pilot Study of the Effect of Maternal Protein Supplementation During Lactation on Childhood Growth N/A
Recruiting NCT04809350 - Human Milk Fortification With Adjustable Versus Targeted Method N/A
Completed NCT02515266 - Additional Protein Fortification in Extremely Low Birth Weight Infants N/A
Recruiting NCT04294368 - Targeted Fortification of Donor Breast Milk in Preterm Infants N/A
Terminated NCT03532555 - Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia N/A
Withdrawn NCT02999945 - Optimal Growth of Preterm Infants With Growth Restriction N/A
Completed NCT01909661 - Tolerance of Infants With Cow's Milk Protein Allergy to Extensively Hydrolyzed Rice Protein or Casein Infant Formulas Phase 2
Not yet recruiting NCT04640805 - Targeted Fortification of Pasteurized Donor Human Milk N/A
Completed NCT01603368 - Prophylactic Probiotics to Extremely Low Birth Weight Prematures Phase 2
Withdrawn NCT01314508 - Increlex Treatment of Children With Chronic Liver Disease and Short Stature N/A
Terminated NCT00490100 - Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 Phase 1/Phase 2
Completed NCT04587271 - Nutritional Impact of Moringa Oleifera Leaf Supplementation in Mothers and Children N/A
Completed NCT01034735 - r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial Phase 1
Active, not recruiting NCT03761498 - Is There a Microbiome Associated With Poor Growth in Preterm Infants?
Not yet recruiting NCT03522558 - Medical Nutrition Therapy for Medically Complex Infants in the Pediatric Outpatient Setting N/A